↓ Skip to main content
What is this page? Embed badge

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

Overview of attention for article published in Frontiers in Pharmacology, November 2022
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
2 X users
patent
1 patent

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
1 Mendeley
Summary X Patents Dimensions citations
So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.